Quoin Pharmaceuticals, Ltd. (QNRX)

NASDAQ: QNRX · IEX Real-Time Price · USD
2.23
-0.23 (-9.35%)
At close: Sep 30, 2022 4:00 PM
2.39
+0.16 (7.17%)
After-hours: Sep 30, 2022 7:34 PM EDT
-9.35%
Market Cap 10.81M
Revenue (ttm) n/a
Net Income (ttm) -5.06M
Shares Out 4.85M
EPS (ttm) -3.63
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 148,321
Open 2.43
Previous Close 2.46
Day's Range 2.21 - 2.52
52-Week Range 2.23 - 237.25
Beta n/a
Analysts Buy
Price Target 13.06 (+485.7%)
Earnings Date Aug 18, 2022

About QNRX

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome. The company also offers three other pipeline products in development, which are also targeting rare skin diseases, including epidermolysis bullosa, Netherton Syndrome, and Scleroderma. Quoin Pharmaceuticals, Ltd. was incorporated in 2018 and is based in Ashburn, Virginia. [Read more...]

Industry Biotechnology
Founded 2018
CEO Shai Yarkoni
Employees 4
Stock Exchange NASDAQ
Ticker Symbol QNRX
Full Company Profile

Financial Performance

Financial numbers in ILS Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for QNRX stock is "Buy." The 12-month stock price forecast is 13.06, which is an increase of 485.65% from the latest price.

Price Target
$13.06
(485.65% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Quoin Pharmaceuticals Establishes Patient Specific Website for Ongoing Netherton Syndrome Clinical Study

Three clinical sites are now fully open; final three sites expected to open imminently Three clinical sites are now fully open; final three sites expected to open imminently

2 weeks ago - GlobeNewsWire

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2022 Financial Results

Initiates clinical trial evaluating lead product candidate, QRX003 for Netherton Syndrome Expands number of commercial partnerships to eight, covering 60 countries Signs Research Agreement to develop a ...

1 month ago - GlobeNewsWire

Quoin Pharmaceuticals to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 18th

ASHBURN, Va., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseas...

1 month ago - GlobeNewsWire

Quoin Pharmaceuticals Announces Closing of $16.8 Million Public Offering

ASHBURN, Va., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseas...

1 month ago - GlobeNewsWire

Quoin Pharmaceuticals Announces Pricing of $16.8 Million Upsized Public Offering

ASHBURN, Va., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseas...

1 month ago - GlobeNewsWire

Quoin Pharmaceuticals and Endo Ventures Limited Enter Into Exclusive Distribution and Supply Agreements

Endo affiliate, Paladin Labs, will commercialize Quoin's lead asset for Netherton Syndrome in Canada Endo affiliate, Paladin Labs, will commercialize Quoin's lead asset for Netherton Syndrome in Canada

2 months ago - GlobeNewsWire

Endo Announces Agreement for Paladin Labs to Develop, Commercialize and Supply Quoin Pharmaceuticals' QRX003 in Canada

The product is under investigation for the treatment of Netherton syndrome, a rare disease DUBLIN , July 15, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that its subsidiar...

2 months ago - PRNewsWire

Quoin Pharmaceuticals Announces Opening of First Clinical Site for Netherton Syndrome Clinical Study

Three Arm, Randomized, Double-Blind, Vehicle Controlled Study Will Test Two Doses of QRX003 Versus Vehicle Three Arm, Randomized, Double-Blind, Vehicle Controlled Study Will Test Two Doses of QRX003 Ver...

2 months ago - GlobeNewsWire

Why Is Quoin Pharmaceuticals (QNRX) Stock Up 93% Today?

QNRX stock is nearly doubling after the company sought permission to cancel an announcement of share sales.  The post Why Is Quoin Pharmaceuticals (QNRX) Stock Up 93% Today?

3 months ago - InvestorPlace

Quoin Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

ASHBURN, Va., June 15, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announ...

3 months ago - GlobeNewsWire

Quoin Pharmaceuticals Announces Licensing and Distribution Agreement with Leading Rare Disease Company for Greater China

Exclusive agreement establishes a major outlet for Quoin's products in the Asian market Exclusive agreement establishes a major outlet for Quoin's products in the Asian market

3 months ago - GlobeNewsWire

Quoin Pharmaceuticals: Strategically Building For Future Success

As the rare disease drug development landscape continues to evolve, Quoin (NASDAQ: QNRX) is focused on staying ahead of its competitors.New York, New York--(Newsfile Corp. - June 14, 2022) - PCG Digital...

3 months ago - Newsfile Corp

Why Are Quoin Pharma Shares Trading Higher Today?

The FDA has accepted Quoin Pharmaceuticals Inc's (NASDAQ: QNRX) Investigational New Drug (IND) application for its licensed formulation, which uses Skinvisible Inc's (OTC: SKVI) Invisicare drug delivery...

3 months ago - Benzinga

Quoin Pharmaceuticals: On Track to Deliver the First FDA-Approved Treatment for Netherton Syndrome

Quoin Pharmaceuticals (QNRX) is developing a potential treatment for a patient population in desperate need. We spoke with CEO, Dr. Michael Myers, to find out more about Netherton Syndrome, a rare and d...

4 months ago - Newsfile Corp

Why Quoin Pharmaceuticals Stock Is Trading Higher

Quoin Pharmaceuticals (NASDAQ: QNRX) shares are trading higher Monday after the company announced it received U.S. Food and Drug Administration clearance to initiate clinical testing for its Investigati...

5 months ago - Benzinga

Quoin Pharmaceuticals Announces FDA Clearance of IND for its Lead Asset, QRX003, for Netherton Syndrome

Quoin Will Initiate Clinical Testing in 1H 2022 Quoin Will Initiate Clinical Testing in 1H 2022

5 months ago - GlobeNewsWire

Quoin Pharmaceuticals Targeting Regulatory Approvals for Lead Candidate for Netherton Syndrome in 2024

As company (QNRX) gains strength, Chief Operating Officer, Denise Carter, talks about what's next for QuoinNew York, New York--(Newsfile Corp. - March 24, 2022) - PCG Digital -- Netherton Syndrome (NS) ...

6 months ago - Newsfile Corp

Quoin Pharmaceuticals Announces Submission of IND for its Lead Asset, QRX003, for Netherton Syndrome

Quoin Anticipates Initiating Clinical Testing in Q2 2022 Quoin Anticipates Initiating Clinical Testing in Q2 2022

6 months ago - GlobeNewsWire

Quoin Pharmaceuticals Submits Scientific Advice Briefing Document to EMA for its Lead Asset, QRX003, for Netherton Sy...

First Step in Development Process of QRX003 for the EU First Step in Development Process of QRX003 for the EU

6 months ago - GlobeNewsWire

Quoin Pharmaceuticals Extends Exclusive Distribution Agreement with ER-Kim for its Lead Asset, QRX003, for Netherton ...

ASHBURN, Va., March 01, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today annou...

7 months ago - GlobeNewsWire

Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with Neopharm for its Lead Asset, QRX003, for Netherton ...

ASHBURN, Va., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announ...

7 months ago - GlobeNewsWire

Changing Lives, Delivering Value: Quoin Pharmaceuticals is Making the Balancing Act Look Easy

New York, New York--(Newsfile Corp. - February 8, 2022) - PCG Digital - Emerging specialty pharma company, Quoin Pharmaceuticals (NASDAQ: QNRX), coined the phrase 'Rare diseases are only rare if you don...

7 months ago - Newsfile Corp

Why Are Quoin Pharma Shares Trading Lower On Wednesday?

Quoin Pharmaceuticals Ltd (NASDAQ: QNRX) has entered into an exclusive distribution agreement with Orpharm LLC for QRX003, for Netherton Syndrome, a rare genetic disease. Under the agreement terms, Orph...

9 months ago - Benzinga

The R&D Sweet Spot: Quoin Pharmaceuticals Delivering Value-Based Drug Development Through Rare and Orphan Disease The...

New York, New York--(Newsfile Corp. - December 14, 2021) - PCG Digital -- Drug development is complex, lengthy and expensive, and not without its risks. Bringing a drug to market takes years, with costs...

9 months ago - Newsfile Corp

Quoin Pharmaceuticals Poised for Rapid Commercialization of Promising Pipeline

New York, New York--(Newsfile Corp. - November 16, 2021) - PCG Digital -- Following a successful merger, one firm is developing and commercializing therapies for rare skin conditions. Quoin Pharmaceutic...

10 months ago - Newsfile Corp